Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B known ✓ | P49841 | 1/20 | 0.35 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2180521 | 0.92 | KDM4E (0.37) | CYP46A1ABL1GSK3BDYRK1ANPC1 | |
| Lithium SCHEMBL2180554 | 0.92 | KDM4E (0.37) | CYP46A1ABL1GSK3BDYRK1ANPC1 | |
| Hydrochloric Acid SCHEMBL2179614 | 0.90 | ABL1 (0.36) | ABL1NPC1RAB9ASMN1; SMN2 | |
| Lithium Ion SCHEMBL1842051 | 0.89 | ACHE (0.36) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1843018 | 0.88 | ABL1 (0.39) | ABL1NPC1RAB9ASMN1; SMN2 | |
| Lithium Ion SCHEMBL1843507 | 0.87 | ACHE (0.41) | ABL1NPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1842877 | 0.87 | ABL1 (0.35) | ABL1NPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1843261 | 0.87 | ABL1 (0.38) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1849172 | 0.85 | TNF (0.37) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1842060 | 0.85 | TNF (0.37) | ABL1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166088-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2011-07-07 | — | — | US | claimed |
| US-20110166088-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166088-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | TOP2B, TOP1, POLI | GSK3B 803/4885CYP46A1 2908/4885ABL1 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.